12 results on '"Le Masson G"'
Search Results
2. Factors associated with survival after early at-home NIV initiation in ALS patients.
- Author
-
Réginault T, Wibart P, Mathis S, Le Masson G, Pillet O, and Grassion L
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Aged, Respiratory Insufficiency therapy, Respiratory Insufficiency mortality, Respiratory Insufficiency etiology, Home Care Services, Amyotrophic Lateral Sclerosis therapy, Amyotrophic Lateral Sclerosis mortality, Amyotrophic Lateral Sclerosis physiopathology, Noninvasive Ventilation
- Abstract
Background: The initiation of early non-invasive ventilation (NIV) often involves a careful balance between tolerance and effectiveness. In amyotrophic lateral sclerosis (ALS) patients, the establishment of a strategy, including the decision to focus on adhering to a cut-off, setting specific targets, or correcting all events, is crucial., Objective: To identify factors at 1 month after early at-home NIV initiation that are associated with improved survival in ALS patients. We explored the impacts of adherence (ADH), quality of treatment, and NIV parameters at 1 month after early at-home NIV initiation on patient survival., Methods: We conducted a retrospective study of 184 ALS patients at the Bordeaux ALS Centre for whom NIV was initiated between September 2017 and June 2021, and we collected data for a minimum period of 2 years after the last patient included. The primary outcome was the risk of death according to baseline characteristics of our population and the NIV parameters and monitoring during the early NIV initiation period. The secondary outcomes were association with NIV ADH during the early NIV initiation period on prognosis, and NIV ADH cut-off for good versus poor prognosis., Results: Among the 178 ALS patients analysed, we found that quality of NIV treatment and device settings did not significantly influence prognosis. However, low ADH was significantly associated with a higher risk of death. The use of NIV for > 5 h/day during the early NIV initiation period was linked to a decreased risk of death [hazard ratio = 0.4; 95% confidence interval: 0.27-0.9]., Conclusion: The use of NIV for > 5 h/day during the early NIV initiation period was associated with increased survival., (© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
3. The various forms of hereditary motor neuron disorders and their historical descriptions.
- Author
-
Mathis S, Beauvais D, Duval F, Solé G, and Le Masson G
- Subjects
- Humans, History, 20th Century, History, 19th Century, Spastic Paraplegia, Hereditary genetics, Spastic Paraplegia, Hereditary history, Motor Neuron Disease history, Motor Neuron Disease genetics
- Abstract
Motor neuron disorders comprise a clinically and pathologically heterogeneous group of neurologic diseases characterized by progressive degeneration of motor neurons (including both sporadic and hereditary diseases), affecting the upper motor neurons, lower motor neurons, or both. Hereditary motor neuron disorders themselves represent a vast and heterogeneous group, with numerous clinical and genetic overlaps that can be a source of error. This narrative review aims at providing an overview of the main types of inherited motor neuron disorders by recounting the stages in their historical descriptions. For practical purposes, this review of the literature sets out their various clinical characteristics and updates the list of all the genes involved in the various forms of inherited motor neuron disorders, including spinal muscular atrophy, familial amyotrophic lateral sclerosis, hereditary spastic paraplegia, distal hereditary motor neuropathies/neuronopathies, Kennedy's disease, riboflavin transporter deficiencies, VCPopathy and the neurogenic scapuloperoneal syndrome., (© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
4. Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study.
- Author
-
Barnay M, Duval F, Solé G, Carla L, Mathis S, and Le Masson G
- Subjects
- Male, Female, Humans, Middle Aged, Aged, Aged, 80 and over, Retrospective Studies, Prospective Studies, Immunoglobulins therapeutic use, Immunization, Passive, Myasthenia Gravis drug therapy
- Abstract
Introduction: To describe the efficacy of subcutaneous immunoglobulin (SCIg) in patients with myasthenia gravis (MG)., Methods: This was a retrospective study conducted in the neuromuscular referral center of Bordeaux (between January 1, 2014 and March 31, 2021) with MG patients treated with SCIg. The main outcome was SCIg efficacy assessed by the before and after SCIg Myasthenia Gravis Foundation of America (MGFA) clinical classification, the duration of hospitalization and the number of days of orotracheal intubation (OTI)., Results: Sixteen patients were included in the study (11 females; 5 males). Nine patients were still treated with SCIg at the end of the study (March 31, 2021) and then underwent prospective follow-up. The average age of the patients was 56.1 (19-83) years. The median duration of MG at onset of SCIg was 37.4 months. Eight patients (50%) remained stable (4 in stage MGFA-IV and 4 in MGFA-III). Eight patients (50%) improved: 3 from MGFA-IV to MGFA-III, 1 from MGFA-IV to MGFA-II, 1 from MGFA-IV to MGFA-I, 2 from MGFA-III to MGFA-II and 1 from MGFA-III to MGFA-I (no patient worsened). The duration of disease progression did not appear to affect the response to SCIg therapy. The number of hospital days per month was significantly reduced after SCIg compared to before, and the number of days in intensive care unit and the number of days of OTI were also reduced. Only minor adverse effects were noted, and 80% of patients were in favor of continuing SCIg., Conclusions: SCIg is a well-tolerated and useful treatment in MG, offering interesting perspectives in the management of MG patients. However, further large-scale prospective studies are needed to confirm these results., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)
- Published
- 2022
- Full Text
- View/download PDF
5. Peripheral neuropathy and livedoid vasculopathy.
- Author
-
Soulages A, Maisonobe T, Auzou P, Petit A, Allenbach Y, Barète S, Skopinski S, Ribeiro E, Jullié ML, Lamant L, Brevet F, Soulages X, Vallat JM, Martin-Négrier ML, Solé G, Duval F, Carla L, Le Masson G, and Mathis S
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Skin pathology, Livedoid Vasculopathy, Mononeuropathies complications, Peripheral Nervous System Diseases diagnosis, Vasculitis complications
- Abstract
Background: Livedoid vasculopathy (LV) is a chronic dermatosis associated with micro-thrombosis of the vessels of the dermis, leading to ischemic lesions and painful skin ulcerations of the lower limbs. This thrombosing occlusive vasculopathy, clearly distinct from 'classical vasculitis' (not related to alteration of vessel walls), may lead to peripheral neuropathy., Objective: To clarify the main clinical, electrophysiological and pathological characteristics of peripheral neuropathy linked to LV., Method: We presented a series of personal cases of peripheral neuropathy due to LV. We also conducted a review of the literature (since the first description of LV in 1974) using multiple combinations of keywords from 'PubMed', 'Google Scholar' and 'ScienceDirect' databases according to the 'Preferred Reporting Items for Systematic reviews and Meta-Analyses' guidelines., Results: We identified 16 patients (6 personal cases and 10 cases from the medical literature). Our personal cases were five females and one male, with a median age (at the onset of cutaneous signs of LV) of 38 (range 25-62). Several types of skin lesions of the lower limbs were observed. Median age at the onset of peripheral neuropathy symptoms was 48 years (range 29-66), with a main clinical and electrophysiological pattern of mononeuropathy multiplex., Discussion: We observed a typical pattern of peripheral neuropathy, mostly mononeuropathy multiplex, whose pathophysiology might be related to occlusions of the small vessels of the nerves, as seen in the dermis. Moreover, LV may also be associated with other types of peripheral neuropathies (sometimes of autoimmune etiology) not directly related to the skin lesions., Conclusion: The 'ischemic form' of peripheral neuropathy linked to LV is mainly responsible for sensory disturbances (with multifocal distribution), sometimes for motor disturbances. This type of peripheral neuropathy has to be distinguished from 'classical vasculitic neuropathies' which are usually treated with antithrombotic therapies., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)
- Published
- 2022
- Full Text
- View/download PDF
6. Neurologic manifestations of giant cell arteritis.
- Author
-
Soulages A, Sibon I, Vallat JM, Ellie E, Bourdain F, Duval F, Carla L, Martin-Négrier ML, Solé G, Laurent C, Monnier A, Le Masson G, and Mathis S
- Subjects
- Humans, Middle Aged, Giant Cell Arteritis complications, Giant Cell Arteritis diagnosis
- Abstract
Giant cell arteritis, the most frequent form of vasculitis in persons over 50 years of age, is a granulomatous chronic vasculitis involving large and medium-sized vessels, most commonly the temporal and other cranial arteries. This common, treatable condition is associated with various clinical symptoms, including neurological ones, affecting both the central and peripheral nervous systems. In this review, we discuss the cranial and extra cranial neurological complications of giant cell arteritis, to help avoid the many pitfalls in the diagnosis of giant cell arteritis., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)
- Published
- 2022
- Full Text
- View/download PDF
7. The ataxic neuropathies.
- Author
-
Mathis S, Duval F, Soulages A, Solé G, and Le Masson G
- Subjects
- Ataxia diagnosis, Ganglia, Spinal, Humans, Spinal Nerve Roots, Peripheral Nervous System Diseases complications, Peripheral Nervous System Diseases diagnosis
- Abstract
Ataxia is a frequent symptom in neurological cases with many causes. Sensory ataxia (due to involvement of the proprioceptive pathways) is observed in conditions affecting the central nervous system (spinal cord disorder) and the peripheral nervous system (peripheral neuropathy). The latter correspond to what we refer to as 'ataxic neuropathies'. Ataxic neuropathies represent a wide and heterogeneous spectrum of disorders that may affect dorsal root nerves, dorsal root ganglia, nerve trunks, distal nerve endings or all of them together. The identification of a predominant sensory ataxia in a case of peripheral neuropathy should raise the possibility of some specific etiologies. We propose here to present the main causes of ataxic neuropathies, which are identified with diagnostic workflows that are dictated by the topography of the likely sites of lesions in the proprioceptive pathway together with the timing of their occurrence (acute, subacute, or chronic)., (© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
8. Epidemics and outbreaks of peripheral nervous system disorders: I. infectious and immune-mediated causes.
- Author
-
Mathis S, Soulages A, Le Masson G, and Vallat JM
- Subjects
- Humans, Epidemics, Guillain-Barre Syndrome epidemiology, Leprosy, Peripheral Nervous System Diseases epidemiology, Peripheral Nervous System Diseases etiology, Poliomyelitis epidemiology
- Abstract
The history of mankind is marked by numerous epidemics, some of which involved diseases of the peripheral nervous system, either infectious or otherwise. We describe here the three main infectious causes of epidemics that affect the peripheral nervous system: leprosy, poliomyelitis and diphtheria. We then discuss the main epidemics of immune-mediated origin.
- Published
- 2021
- Full Text
- View/download PDF
9. Epidemics and outbreaks of peripheral nervous system disorders: II. Toxic and nutritional causes.
- Author
-
Mathis S, Soulages A, Vallat JM, and Le Masson G
- Subjects
- Causality, Disease Outbreaks, Humans, Communicable Diseases, Epidemics, Peripheral Nervous System Diseases epidemiology, Peripheral Nervous System Diseases etiology
- Abstract
Peripheral neuropathies have various causes, both infectious and non-infectious. When we think of "epidemics", we often refer to an infectious or even post-infectious origin. Nevertheless, the history of mankind is marked by episodes of epidemics of peripheral neuropathies of non-infectious nature, either of nutritional or toxic origin: we present here the main causes of such epidemics.
- Published
- 2021
- Full Text
- View/download PDF
10. Correction to: Epidemics and outbreaks of peripheral nervous system disorders: I. infectious and immune-mediated causes.
- Author
-
Mathis S, Soulages A, Le Masson G, and Vallat JM
- Published
- 2021
- Full Text
- View/download PDF
11. Prognostic factor of poor outcome in anti-MAG neuropathy: clinical and electrophysiological analysis of a French Cohort.
- Author
-
Tang MH, Mathis S, Duffau P, Cazenave P, Solé G, Duval F, Soulages A, and Le Masson G
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, France, Humans, Male, Middle Aged, Outcome Assessment, Health Care, Polyradiculoneuropathy classification, Prognosis, Retrospective Studies, Disease Progression, Electrophysiological Phenomena, Immunologic Factors administration & dosage, Myelin-Associated Glycoprotein immunology, Polyradiculoneuropathy drug therapy, Polyradiculoneuropathy pathology, Polyradiculoneuropathy physiopathology
- Abstract
Background: Anti-MAG polyneuropathy (anti-MAG PN) is an immune-mediated peripheral sensorimotor neuropathy characterized by distal demyelination and ataxia. However, this disorder, unlike other immune-mediated neuropathies, is difficult to treat in most cases., Method: We retrospectively collected all anti-MAG PN patients followed in two hospitals for a period of 12 years to determine prognostic factors, especially those that indicated a good response to the various therapeutic strategies used., Results: Forty-seven patients were included in the study; of these, 61% had a classical 'distal demyelinating pattern', 34.2% had a 'CIDP-like pattern', and the others had an 'axonal pattern'. The most commonly used treatments were intravenous immunoglobulin (IVIg) as the first-line treatment and rituximab as the second- or third-line treatment. No prognostic factor was identified for IVIg, but electrophysiological parameters at onset were better in patients with a good response to rituximab than in non-responder patients, even though mild or high disability was observed in nearly half the patients at last examination., Conclusion: Even though disability seems to progress in most cases despite the treatments used, our results suggest that an early electrophysiological reduction in sensory nerves could be considered a 'red flag' for the prompt initiation of rituximab to try to delay long-term disability.
- Published
- 2020
- Full Text
- View/download PDF
12. Myopathy and scleromyxedema.
- Author
-
Soulages A, Tang HM, Pham-Ledard A, Négrier-Leibreich ML, Cosnard A, Duval F, Solé G, Carla L, Le Masson G, and Mathis S
- Subjects
- Aged, Humans, Immunoglobulins, Intravenous administration & dosage, Lysosomal Storage Diseases drug therapy, Male, Muscular Diseases drug therapy, Scleromyxedema drug therapy, Lysosomal Storage Diseases complications, Lysosomal Storage Diseases diagnostic imaging, Muscular Diseases complications, Muscular Diseases diagnostic imaging, Scleromyxedema complications, Scleromyxedema diagnostic imaging
- Abstract
Scleromyxedema is a chronic, idiopathic disorder associated with monoclonal gammopathy, and characterized by dermal mucin deposition. However, systemic manifestations are frequent, including neuromuscular symptoms. We herein present a 71-year-old man who developed a vacuolar myopathy in a context of a known scleromyxedema, and we compare our observation with the nineteen other cases found in the medical literature. Such an association (especially with suggestive skin abnormalities) has to be known for two reasons. First, this diagnosis might be quite challenging because the myopathy may precede the typical skin changes. Secondly, conversely to other forms of vacuolar myopathy, some of the symptoms may respond (even partially) to immunomodulatory and/or immunosuppressant therapeutics.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.